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ARTICLE
Blood monocyte transcriptome and epigenome
analyses reveal loci associated with human
atherosclerosis
Yongmei Liu1, Lindsay M. Reynolds 1, Jingzhong Ding2, Li Hou1, Kurt Lohman3, Tracey Young1, Wei Cui2,
Zhiqing Huang4, Carole Grenier4, Ma Wan5, Hendrik G. Stunnenberg6, David Siscovick7, Lifang Hou8,
Bruce M. Psaty9,10, Stephen S. Rich11, Jerome I. Rotter12, Joel D. Kaufman 13, Gregory L. Burke1, Susan Murphy4,
David R. Jacobs Jr14, Wendy Post15, Ina Hoeschele16, Douglas A. Bell5, David Herrington2, John S. Parks17,
Russell P. Tracy18, Charles E. McCall17 & James H. Stein19
Little is known regarding the epigenetic basis of atherosclerosis. Here we present the
CD14+ blood monocyte transcriptome and epigenome signatures associated with human
atherosclerosis. The transcriptome signature includes transcription coactivator, ARID5B,
which is known to form a chromatin derepressor complex with a histone H3K9Me2-speciﬁc
demethylase and promote adipogenesis and smooth muscle development. ARID5B CpG
(cg25953130) methylation is inversely associated with both ARID5B expression and
atherosclerosis, consistent with this CpG residing in an ARID5B enhancer region, based on
chromatin capture and histone marks data. Mediation analysis supports assumptions that
ARID5B expression mediates effects of cg25953130 methylation and several cardiovascular
disease risk factors on atherosclerotic burden. In lipopolysaccharide-stimulated human
THP1 monocytes, ARID5B knockdown reduced expression of genes involved in
atherosclerosis-related inﬂammatory and lipid metabolism pathways, and inhibited cell
migration and phagocytosis. These data suggest that ARID5B expression, possibly
regulated by an epigenetically controlled enhancer, promotes atherosclerosis by
dysregulating immunometabolism towards a chronic inﬂammatory phenotype.
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Epigenomics and transcriptomics can illuminate the interplaybetween the genome and its environment and may provideinsights into the molecular basis of complex diseases,
including cardiovascular disease (CVD)1–5. Epigenetic targeting
also is an attractive treatment strategy for reordering dysregulated
gene expression. To date, epigenome-wide studies of CVD traits
are limited6 and their interpretation is potentially complicated by
use of data from mixed cell types, which may obscure cell-type-
speciﬁc functional mechanisms. Monocytes and their derived
macrophages are key factors in inﬂammation that contribute
to the development of many chronic diseases, including
atherosclerosis7–10.
We recently reported the blood monocyte epigenome and
transcriptome signatures of several CVD risk factors, including
age, obesity, and cigarette smoking11–14. In this study, we identify
transcriptome and methylome features that are associated with
atherosclerosis. In addition to traditional CVD risk factors,
we also integrate these ﬁndings with histone modiﬁcation,
DNase-seq, Hi-C (genome chromosome conformation capture),
and ChIA-PET (chromatin interaction analysis by paired-end
tag) sequencing data and in vitro functional data, in order to
characterize novel molecular mechanisms of atherosclerosis. We
show emerging evidence for a potential role of ARID5B in
atherogenesis, and for an epigenetically controlled regulatory site
of ARID5B expression.
Results
Clinical data and sample characteristic. The Multi-Ethnic Study
of Atherosclerosis (MESA) is a multi-site, longitudinal study
designed to investigate the prevalence, correlates, and progression
of subclinical CVD in a population cohort of 6814 participants.
Since its inception in 2000, ﬁve clinic visits have collected
extensive clinical, socio-demographic, lifestyle, behavior, labora-
tory, nutrition, and medication data15. At Exam 5, carotid
ultrasound and computed tomography (CT), were used to
quantify carotid plaque burden (carotid plaque score, range 0–12)
and coronary artery calciﬁcation (CAC Agatston score),
respectively. These two measures of atherosclerosis burden
independently predict future CVD events in MESA and other
cohorts16–19 (distribution of scores presented in Supplementary
Fig. 1). Table 1 shows characteristics of the MESA participants at
Exam 5, overall and stratiﬁed by study site (study site 1: N= 709,
site 2: N= 499), including demographics (age, sex, race/ethnicity,
and study site), traditional CVD risk factors (cigarette smoking,
body mass index (BMI), high- and low-density lipoprotein
cholesterol (HDL-C and LDL-C), hypertension, type II diabetes
mellitus (T2DM)), atherosclerosis burden measures, prevalent
CVD, and statin use. The transcriptome and methylome of
monocytes puriﬁed at MESA Exam 5 were proﬁled concurrently.
In a separate effort to evaluate reproducibility of single-time
measures, we showed high consistency of repeated Illumina
microarray data over ﬁve months (Supplementary Fig. 2), sug-
gesting both RNA expression and DNA methylation at most loci
can be stable over time in an individual.
Blood leukocyte count and atherosclerosis. Total white blood
cell (WBC) count and its constituent subtypes were measured for
all samples before monocyte puriﬁcation, which provided the
absolute monocyte count. Higher monocyte count, but not
monocyte percentage or other leukocyte count, was marginally
associated with carotid plaque score and CAC (natural log
(carotid plaque score/CAC + 1), P= 0.026 with 0.4% of variability
explained, and P= 0.079, respectively), in agreement with pre-
vious reports20. We used positive immunoselection (magnetic
beads)21 to produce samples of monocytes with >90% purity.
Residual contamination with neutrophils, B cells, T cells,
and natural killer cells was estimated as previously reported22.
Likewise, the generally small percentage of CD14+ monocytes
that are also CD16+ (~10%)23 was estimated based on expression
of FCGR3a (CD16a). Neither the surrogates of residual cell
Table 1 Population characteristics at MESA Exam 5
Characteristicsa Overall (N= 1208) By site
Study 1 (JHU + CO) (N= 709) Study 2 (UMN +WFU) (N= 499)
Demographic
Age (years) 70± 9 70± 9 69± 9
Sex (% female) 51.4 55.0 46.3
Race/ethnicity
African American (%) 21.5 36.1 0.8
Hispanic (%) 32.6 29.3 37.3
Caucasian (%) 45.9 34.6 61.9
Cigarette smoking
Former (%) 51.7 49.1 55.5
Current (%) 9.1 8.1 10.5
Clinical and laboratory
BMI, (kg m−2) 30± 6 30± 6 30± 5
LDL-C (mg dl−1) 105± 32 107± 33 102± 30
HDL-C (mg dl−1) 54± 16 57± 17 50± 13
Impaired glucose tolerance (%) 45.6 44.3 47.5
Diabetes (%) 23.0 25.2 19.8
Hypertension (%) 60.9 63.8 56.6
Carotid plaque score, median (IQR) 2 (0–4) 2 (0–3) 2 (0–4)
Coronary artery calcium score, median (IQR) 46 (0–305) 32 (0–227) 76 (0–397)
Prevalent CVD (%) 5.3 4.2 6.8
Statin use (%) 38.5 35.7 42.5
BMI body mass index, CO Columbia University, CVD cardiovascular disease, HDL-C high-density lipoprotein-cholesterol, IQR interquartile range, JHU John Hopkins University, LDL-C low-density
lipoprotein-cholesterol, UMN University of Minnesota, WFU Wake Forest University
aPlus-minus values are means± SD
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contamination nor the % of CD14+ CD16+ cells was associated
with the measures of atherosclerosis.
Transcriptome signature of atherosclerosis. Transcriptomic
studies of atherosclerosis in mouse models and in humans24–26
have been reported. However, no consensus atherosclerosis
biomarkers or pathways have been identiﬁed. Of the 10,989
unique genes with RNA expression detectable in monocytes, we
identiﬁed genes with expression associated with carotid plaque
score (n= 2) and CAC (n= 13) at a q-value-based false discovery
rate (FDR)27 of 0.05 after adjusting for demographics (Fig. 1a, b).
Using the FDR level of 0.05 for the genome-wide search,
we would inevitably miss signals with small effect size due to
the limited statistical power for the sample size we have; thus,
additional signals for FDR of 0.20 were shown in Supplementary
Table 1 (21 gene transcripts with carotid plaque and 104 gene
transcripts with CAC). Expression of two genes, ARID5B and
PDLIM7 (PDZ and LIM domain protein 7), were positively
associated with both measures of atherosclerosis (FDR≤ 0.05);
ARID5B was most signiﬁcantly associated with carotid
plaque score (P= 6.30 × 10−8, FDR= 1.08 × 10−3; with CAC:
P= 2.47 × 10−5, FDR= 0.03). ARID5B has a key metabolic role in
adipose, liver, and smooth muscle, and was previously implicated
in lipid metabolism and adipogenesis in mice28, 29. PDLIM7 is an
actin and protein kinase adaptor that promotes mineralization,
which might be relevant to plaques with calcium. The most sig-
niﬁcant signal associated with CAC was lower expression of
CACNA2D3 (calcium channel, voltage-dependent, alpha 2/delta
subunit 3; P= 2.08 × 10−8, FDR= 3.19 × 10−4; with carotid
plaque: P= 6.71 × 10−3, FDR= 0.40) a tumor suppressor gene
that can induce mitochondrial-mediated apoptosis30. In addition,
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Fig. 1 Transcriptomic associations with carotid plaque and CAC scores in 1208 MESA participants. The two volcano plots showing effect size (β) of
−log10(p-value) for associations of each mRNA expression (for 10,989 unique mRNA expression) with (a) carotid plaque score and (b) CAC. The red line
illustrates the threshold for an FDR≤ 0.05 (linear regression adjusting for age, sex, race, and study site). Expression of ARID5B and PDLIM7 (bolded) were
associated with both carotid plaque and CAC score; green star indicates mRNA expression most signiﬁcantly associated with carotid plaque or CAC. The
two forest plots showing the direction and effect size (β) for associations of each mRNA expression (in a, b) with (c) carotid plaque score and (d) CAC
score in the full model (including traditional CVD risk factors), overall and by the two independent studies (study 1: JHU + CO, red; study 2: UMN+WFU,
blue); ‡ signiﬁcantly different effect sizes observed by study (pinteraction< 0.05). e The forest plot showing ARID5B mRNA expression associations with
carotid plaque, stratiﬁed by age (< 65 years and≥ 65 years), sex, ethnicity/race, CVD, and statin use
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adjusting for other traditional CVD risk factors and statin use
(in a model designated as the full model) had minimal impact on
the signiﬁcant associations (Fig. 1c, d). All of these associations
had a consistent direction of effect across the independent study
sites, in particular for three genes (ARID5B, TSPYL1, and ADM),
which were cross-validated (P< 0.05, Fig. 1c, d). Race/ethnicity-
and sex-speciﬁc analyses also were consistent across various strata
(Supplementary Table 2). For the top signal, ARID5B, the
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Fig. 2Methylomic associations with carotid plaque and CAC scores in 1208 MESA participants. The two Manhattan plots showing chromosomal locations
of −log10(p-value) for associations of each CpG site (for 484,817 CpG sites) with (a) carotid plaque score and (b) CAC score. The red line illustrates the
threshold for an FDR≤ 0.05; linear regression adjusting for age, sex, race, and study site). One CpG at ILVBL (bolded, green dot) was associated with both
carotid plaque and CAC; green star indicates CpGs most signiﬁcantly associated with carotid plaque or CAC. Notably, for ARID5B, both methylation
(cg25953130, green dot) and mRNA expression were signiﬁcantly associated with carotid plaque score. The two forest plots showing the direction
and effect size (β) for associations of each CpG sites (in a, b, the most signiﬁcant association at each unique loci is shown) with (c) carotid plaque
score and (d) CAC in the full model (including traditional CVD risk factors), overall and by the two independent studies (study 1: JHU + CO, red; study 2:
UMN+WFU, blue); ‡ signiﬁcantly different effect sizes observed by study (pinteraction< 0.05). e The forest plot showing ARID5B cg25953130 methylation
associations with carotid plaque score, stratiﬁed by age (< 65 years and≥ 65 years), sex, ethnicity/race, CVD, and statin use
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Fig. 3 In vivo and in silico functional analysis of ARID5B CpG cg25953130. a ARID5B mRNA expression (y axis; normalized value) is signiﬁcantly negatively
correlated (Pearson’s r) with methylation of a CpG (cg25953130) in 1264 CD14+ samples from MESA participants. b A regional association plot of ARID5B
CpG methylation with carotid plaque score in MESA (y axis: −log10 (p-value), x axis: position on chromosome (chr) 10) is shown in the top panel; the bottom
panel shows the ARID5B expression-associated CpG (cg25953130, chr10:63,753,550, hg19, indicated by the light blue line) located in an ARID5B intron,
overlaps a DNase hypersensitive site in a CD14+ sample from BLUEPRINT, histone marks indicative of a strong enhancer/promoter in a CD14+ and B-cell
line sample from BLUEPRINT and ENCODE (see Supplementary Fig. 3 for ChromHMM color code), as well as a transcription factor binding site for EP300,
detected in a neuroblastoma cell line (SK-N-SH_RA). c A physical interaction is detected between the ARID5B promoter and the region near the ARID5B
CpG cg25953130 by both HiC and ChIA-PET data. The heatmap (white, low; red, high; top panel) graphically displays Hi-C interaction counts
(the normalized number of contacts between a pair of loci) for the large region surrounding ARID5B in a B-cell line (GM12878; reported by Rao et al.39);
active enhancer marks (H3K27ac and H3K4me1 in GM12878 from ENCODE) are shown below; the bottom panel zooms in on ARID5B (blue highlighted
region) Hi-C interaction. There were 1,937 contacts between the ARID5B promoter and the cg25953130 region. Below the Hi-C interaction is a depiction of
detected ChIA-PET interactions (chromatin interaction analysis by paired-end tag sequencing) for the region ﬂanking ARID5B in the B-cell line (GM12878;
reported by Heidari et al.41), represented by blue curves
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associations with carotid plaque were consistent in direction and
nominally signiﬁcant across subgroups of age (< or ≥ 65 years),
sex, and statin use (Fig. 1e). Results utilizing RNA-sequencing-
derived expression levels from a subset (N= 354) of the monocyte
samples validated signiﬁcant associations between ARID5B
and CAC (β± SE= 0.45± 0.20, P= 0.03) and carotid plaque
(β± SE= 0.13± 0.06, P= 0.04).
To identify network modules of highly correlated transcripts in
an unbiased manner, we applied the weighted gene co-expression
network analysis (WGCNA)31 and identiﬁed 40 co-expressed
gene network modules. Three modules signiﬁcantly (FDR≤ 0.05)
associated with CAC (Supplementary Table 3), including a
cholesterol metabolism transcriptional network (CMTN) with 12
functionally coupled genes that was also associated with carotid
plaque. The CMTN eigengene (the ﬁrst principal component) of
CMTN was associated with a transcriptional proﬁle expected
to increase intracellular cholesterol, including upregulation of
cholesterol uptake (LDLR and MYLIP), and cholesterol and fatty
acid synthesis genes (HMGCS1, FDFT1, SQLE, CYP51A1,
SC4MOL, SC5DL, SCD, and FADS1), as well as downregulation
of cholesterol efﬂux genes (ABCG1 and ABCA1). We recently
reported the CMTN being a signature feature of obesity, which
was associated with CAC (P= 3.34 × 10−4)13. Here we further
showed the CMTN was positively associated with carotid plaque
(P= 2.31 × 10−4; FDR= 0.009). Among the CMTN members,
LDLR expression was most signiﬁcantly associated with CAC
(P= 1.34 × 10−4, FDR= 0.10) and ABCG1 expression was most
signiﬁcantly associated with carotid plaque (P= 1.48 × 10−4,
FDR= 0.18, Supplementary Table 1). The other two network
modules signiﬁcantly (FDR≤ 0.05) associated with CAC were
enriched with genes involved in phagosome formation (mod-
ule 39; FDR= 1.32 × 10−2) and migration of cells (module 23;
FDR= 3.96 × 10−2; Supplementary Table 3).
Methylome signature of atherosclerosis. Of the 484,817 CpG
sites, 31 and 7 had methylation signiﬁcantly associated with
carotid plaque and CAC, respectively, including 1 CpG
(cg23661483 in exon of ILVBL) associated with both carotid
plaque and CAC (FDR≤ 0.05, adjusting for demographics,
Fig. 2a, b and Supplementary Table 4 showing additional signals
for FDR≤ 0.10). The most signiﬁcant CpG (cg06126421)
associated with carotid plaque score (P= 2.00 × 10−10,
FDR= 8.91 × 10−5) is an intergenic CpG, which recently was
reported as one of the most signiﬁcant smoking-associated
methylation sites genome wide32. Notably, the carotid plaque-
associated methylation sites include one CpG in ARID5B
(cg25953130, intron 2, P= 4.31 × 10−7, FDR= 0.01), which tends
to be hypomethylated in the individuals with higher carotid
plaque scores. Similar results were found between cg25953130
methylation and CAC (P= 6.80 × 10−5, FDR= 0.32).
The 37 differentially methylated sites associated with carotid
plaque or CAC presented higher variable CpG methylation levels
(across MESA population) with the interdecile range of the
percentage of methylation (measured by β-value33) ranging from
4 to 24% (median: 10%), compared with the whole methylome
(median: 4%). The majority of the methylation sites associated
with carotid plaque or CAC had inverse associations with
the atherosclerosis measures (Supplementary Table 4). The 37
atherosclerosis-associated CpGs are distributed among 30 unique
genomic loci.
Additional adjustments in the full model had minimal impact
on the signiﬁcant associations, which were also consistent across
the two study sites for the majority (61%) of differentially
methylated sites (P< 0.05, as shown for each unique loci in
Fig. 2c, d). Race/ethnicity- and sex-speciﬁc analyses also showed
high consistency across the various strata (Supplementary
Table 5), suggesting shared effects across ancestries. At the
genome-wide level, race/ethnicity-speciﬁc analyses did not
uncover additional signiﬁcant associations. The associations of
ARID5B methylation (cg25953130, intron) with carotid plaque
were consistent in direction and nominally signiﬁcant across
subgroups of age (< or≥ 65 years), sex, CVD status, and statin
use (Fig. 2e). Pyrosequencing derived methylation of cg25953130
from a subset (n= 90) of the monocyte samples signiﬁcantly
correlated with microarray-based methylation levels (r= 0.92,
P= 5.2 × 10−37) and validated signiﬁcant associations between
cg25953130 methylation and carotid plaque (β± SE= −0.07± 0.03,
P= 6.31 × 10−3).
In vivo and in silico functional validation. DNA methylation
has been viewed as an important potential regulator of gene
expression34. To prioritize the list of differentially methylated
CpGs, we assessed expression-associated methylation sites (eMS)
reported in the same monocyte samples by our previous study22.
We identiﬁed ﬁve atherosclerosis-associated CpGs whose
methylation was signiﬁcantly related to messenger RNA expres-
sion of at least one nearby gene (Supplementary Table 6). Out of
the ﬁve atherosclerosis-associated eMS, four had methylation
correlated with mRNA expression proﬁles that were nominally
(P< 0.05) associated with atherosclerosis, including expression
of SC4MOL. The CpG most signiﬁcantly associated with
CAC (cg05119988, located in the 5′-untranslated region of
SC4MOL) signiﬁcantly correlated (r= −0.17, P= 1.2 × 10−10,
FDR = 7.3 × 10−8) with mRNA expression of SC4MOL, a member
of the identiﬁed CMNT, which was nominally associated with both
carotid plaque and CAC. The SC4MOL eMS resides in a predicted
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Fig. 4 ARID5B expression and methylation are associated with subclinical and clinical CVD risk. Odds ratio of subclinical and clinical CVD (in the full model
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weak promoter region of a B-cell line; however, this region was
identiﬁed as heterochromatin in monocytes (using ChromHMM35
for histone modiﬁcation data from BLUEPRINT36, 37, Supple-
mentary Fig. 3 and Supplementary Tables 4 and 6).
The ARID5B CpG (cg25953130) was the only CpG
site signiﬁcantly associated with expression of ARID5B
(P= 3.84 × 10−14, FDR= 5.70 × 10−6; Fig. 3a). As shown in
Fig. 3b, it overlaps a DNase hypersensitive hotspot (BLUEPRINT
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monocyte data36, 37), a predicted strong enhancer (using
both monocyte and B-cell line histone mark data from the
BLUEPRINT36, 37 and ENCODE38 projects, respectively), and a
transcription factor-binding site occupied by EP300 (in a
neuroblastoma cell line). More importantly, chromatin-capture
sequencing technologies (both Hi-C and ChIA-PET) conﬁrmed
direct interactions between regions in the ARID5B cg25953130
locus and the ARID5B promoter region in B-cell line39–42
(Fig. 3c). Our data, together with the publically available
functional data, strongly support the presence of an ARID5B
regulatory region in the ARID5B gene body ﬂanking ARID5B
cg25953130.
To test whether the assumed methylation effects on athero-
sclerosis burden were mediated through its associated mRNA
expression, we used structural equation modelling (SEM) with
bootstrapping (R package lavaan43) to perform mediation
analyses. We showed that ARID5B mRNA expression signiﬁ-
cantly mediated 15% and 14% of the total effect of this ARID5B
CpG on carotid plaque score (indirect effect, P= 2.1 × 10−4) and
CAC (P= 2.1 × 10−3), respectively.
The inverse association between methylation of this ARID5B
CpG and carotid plaque score after adjusting for ARID5B
expression (direct effect) was also signiﬁcant. Jointly, the
associations of ARID5B gene expression and methylation levels
with atherosclerosis explain an additional 2.3% of the variability
in carotid plaque score beyond well-known CVD risk factors and
statin use. The effect sizes of ARID5B gene expression and
methylation levels associating with carotid plaque score are
higher than the effect sizes of T2DM (1% of variability) or
hypertension (0.9%) in the same model. These data suggest that
different types of related genomic features (mRNA expression
and DNA methylation) may offer additive values in prediction of
CVD susceptibility.
To further demonstrate the clinical relevance of ARID5B, we
associated the tertiles of ARID5B mRNA expression and ARID5B
cg25953130 methylation with presence of carotid plaque (deﬁned
as carotid plaque score greater than zero, N= 816 cases), presence
of CAC (deﬁned as CAC > 0, N= 844 cases), and prevalent CVD
(history of a coronary heart event or stroke, N= 64 cases).
ARID5B mRNA expression was positively associated with the
presence of carotid plaque (third tertile odds ratio = 2.10, 95%
conﬁdence interval (CI): 1.42–3.09, P= 1.87 × 10−4), presence
of CAC (third tertile odds ratio= 2.10, 95% CI: 1.42–3.09,
P= 1.87 × 10−4), and prevalent CVD (third tertile odds
ratio= 2.33, 95% CI: 1.08–5.02, P= 3.12 × 10−2, Fig. 4a), whereas
ARID5B cg25953130 methylation was inversely associated with
the presence of carotid plaque (third tertile odds ratio= 0.64, 95%
CI: 0.45–0.92, P= 1.59 × 10−2) and presence of CAC (third tertile
odds ratio= 0.64, 95% CI: 0.45–0.92, P= 1.59 × 10−2, Fig. 4b) in
the full model. To examine the dose–response relationship
between ARID5B and extent of atherosclerosis, which may
indicate their potential contribution to the progression of plaques,
we performed linear regression analysis while excluding those
with zero value of carotid plaque score. The associations with
carotid plaque score remain signiﬁcant for the ARID5B mRNA
expression (unique variability explained: 1.2%, P= 1.1 × 10−3)
and cg25953130 methylation (unique variability explained: 0.73%,
P= 1.1 × 10−2).
Identiﬁed genomic features and known CVD risk factors.
Among the atherosclerosis-associated genomic features, eight
mRNA (Supplementary Table 7) and 33 CpGs (Supplementary
Table 8) were also associated with one or more traditional CVD
risk factors, particularly demographics (age, sex, and race/
ethnicity), cigarette smoking, and obesity. For three mRNA and
29 CpGs (bolded in Supplementary Table 7 and Supplementary
Table 8), the predicted effects of the majority of CVD risk factors
on atherosclerosis that were mediated through the genomic
features have the similar direction as the observed associations
between the CVD risk factors and the measure of atherosclerosis.
ARID5B expression was positively associated with many
CVD risk factors (FDR< 0.05 with adjustment for demographic
variables), such as age, (P= 2.06 × 10−13), BMI (P= 1.67 × 10−8),
T2DM (P= 3.43 × 10−5), and inﬂammatory stress (measured by
plasma interleukin-6 levels (IL-6; P= 1.36 × 10−10), and inversely
associated with HDL-C levels (P= 6.86 × 10−6). ARID5B
methylation (cg25953130) was associated inversely with age
(P= 3.33 × 10−11) and plasma IL-6 levels (P= 0.004), and the
ARID5B CpG tended to be hypomethylated in current smokers
(P= 7.19 × 10−7). Although we cannot be certain of causality,
if we assume ARID5B to be in fact causal, mediation analyses
showed the expression of ARID5B signiﬁcantly mediated 10 and
25% of the total effect of age and IL-6 on carotid plaque score
(P= 7.46 × 10−6, 4.33 × 10−5, respectively), and the ARID5B
methylation signiﬁcantly mediated 7 and 10% of the total
effect of age and IL-6 on carotid plaque score (P= 2.57 × 10−4,
8.28 × 10−3, respectively).
ARID5B RNA expression and methylation in CD4+ T cells. To
examine the ARID5B expression and methylation across cell
types, similar analyses were performed in a subset of 517 MESA
CD4+ T-cell samples. Correlations for ARID5B expression and
methylation between monocyte and T cells were weak (r= 0.12
and 0.30, respectively). Within T-cell samples, ARID5B expres-
sion was inversely correlated with cg25953130 methylation
(r= −0.45, P= 1.27 × 10−31), as seen in monocytes. The ARID5B
mRNA and cg25953130 methylation associations with carotid
plaque and CAC were not signiﬁcant in T-cell samples (P> 0.05),
but remained statistically signiﬁcant (p ranges from 3.8 × 10−3 to
7.2 × 10−3) when analyzed in the monocyte samples from
the same subset. In the same data, however, we observed the
association of AHRR cg05575921 with carotid plaque score and
CAC score in T-cell samples (P= 3.18 × 10−5 and 5.89 × 10−5,
respectively), with a strong correlation between the two cell types
for the AHRRmethylation site (r= 0.97). AHRR hypomethylation
is a well-known, robust biomarker of smoking that we recently
linked to carotid plaque score in MESA14. These results
demonstrate examples of both potential cell-type-speciﬁc and
shared genomic features in relation to burden of atherosclerosis.
Functional evaluation of ARID5B using in vitro models.
Although little is known about the majority of identiﬁed genomic
features, pleotropic effects of ARID5B in adipogenesis28,
chondrogenesis44, autoimmune diseases45, 46, lipid metabolism29,
and smooth muscle cell differentiation47 have been previously
reported. As a transcription coactivator that is part of the
H3K9me2 demethylase complex with PHD ﬁnger protein 2,
ARID5B is expected to activate its target genes by removing the
repressive H3K9Me2 histone mark (demethylation of H3K9me2)
from the promoter region of target genes44, 48. To evaluate the
functional role of ARID5B in monocytes/macrophages, we
examined the effects of its knockdown on transcriptomic proﬁles
in lipopolysaccharide (LPS)-stimulated human THP1 monocytes
in two independent experiments (LPS: 100 ngml−1, n= 4 per
group at each experiment).
ARID5B mRNA knockdown efﬁciency was 85 and 76% in the
two experiments (Supplementary Fig. 4); both consistently
showed that ARID5B knockdown decreased expression of 1,320
genes and increased expression of 1,162 genes (FDR< 0.005 in
the discovery set and FDR< 0.05 in the replication set;
Supplementary Data 1).The 2,482 ARID5B-modiﬁed genes
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displayed a signiﬁcant overrepresentation of related pathways
including inﬂammatory/immune response, chemotaxis, migra-
tion, extravasation signaling, and phagocytosis, and also the lipid
synthesis functional pathway, compared with the background list
of genes detectable on the array (enrichment FDR< 0.05, Fig. 5a,
full list of genes provided in Supplementary Table 9). Enriched
biofunctions and canonical pathways in the inﬂammatory
response pathway consisted of mainly downregulated genes,
including key proinﬂammatory cytokines (e.g., tumor necrosis
factor (TNF) and IL-1a), activator and effector cytokines from the
type I interferon signaling pathway (e.g., IRF3, IFNB1, STAT1,
and STAT2), and antigen processing and presentation genes (e.g.,
major histocompatibility complex class II cell surface receptors:
HLA-DRA and HLA-DRBs, Supplementary Fig. 4 and bolded
in Supplementary Table 9), collectively indicating decreased
pathway activation. Decreased expression of genes in two of the
enriched pathways, phagocytosis, and lipid synthesis (shown in
red in Supplementary Table 9), overlapped with the members of
two atherosclerosis-associated networks we identiﬁed in MESA
(CMTN and module 39—enriched for the phagosome formation
pathway, Supplementary Table 3), which suggests ARID5B
may contribute to the gene network associations with
atherosclerosis.
To interrogate the potential pro-inﬂammatory role that
ARID5B may have, we repeated the third ARID5B knockdown
experiment and performed enzyme-linked immunosorbent assay
(ELISA) assays of culture media for IL-1A, the pro-inﬂammatory
cytokine that was most signiﬁcantly reduced by ARID5B mRNA
knockdown (FDR: 3.79 × 10−8, 4.48 × 10−4 in the ﬁrst two
experiments, Supplementary Data 1). ARID5B knockdown
decreased levels of both IL1A mRNA (P= 0.02) in the THP1-
monocytes and IL-1A protein expression (P= 4.28 × 10−4) in
their culture media, as shown in Fig. 5b.
To further examine the effects of ARID5B knockdown on
cellular functions suggested by the transcriptomic proﬁle changes,
we performed THP1-monoctye migration and phagocytosis
assays. ARID5B knockdown suppressed monocyte migration
(P= 3 × 10−7, 0.004 in experiment 1 and 2, respectively, Fig. 5c).
ARID5B knockdown also moderately inhibited monocyte
phagocytosis (P= 0.008) as shown in Fig. 5c.
Discussion
In summary, using puriﬁed blood monocytes (CD14+) we dis-
covered many epigenome and transcriptome features of athero-
sclerosis independent of well-known CVD risk factors, including
several robust signals that were cross-validated by two state-of-art
imaging measures of atherosclerosis, at different study sites, in
two different arterial beds, and in both males and females. We
further demonstrated that most of the atherosclerosis-associated
genomic features were associated with traditional CVD risk
factors, but not reported genetic risk variants. Although causal
directions could not be inferred in our observational study, we
have prioritized genomic features that link to well-established
CVD risk factors and atherosclerosis, implicating the underlying
mechanisms of traditional CVD risk factors (e.g., age and obesity)
in atherogenesis partially mediated through ARID5B. Our data
suggest two pathways for further investigation: (1) whether in
the causal pathway or reﬂective of disease, epigenome, and
transcriptome features in circulating monocytes are potential
“biosensors” that might be useful for detecting early signs of
metabolic disorders and elevated CVD risk; and (2) if in the
causal pathway, several new candidates are emerging for potential
intervention. Our study contributes to a larger list of athero-
sclerosis biomarkers and provides accessibility to unique multi-
omics databases with well-characterized clinical phenotypes.
Finally, we contribute to the rapidly evolving picture of human
gene expression regulation that promises to be formidable in both
scope and complexity49.
In particular, we identiﬁed a novel molecular link between
ARID5B (transcription coactivator for histone H3K9me2
demethylation) mRNA expression and atherosclerosis, as well as
the ARID5B CpG DNA methylation alteration that was inversely
associated with both ARID5B expression and atherosclerosis.
It is worth noting that the observed inverse association of the
ARID5B methylation site with its expression is not sufﬁcient to
support its causal role, as methylation change could be caused by
additional transcription factors binding to this enhancer region.
Local ﬁne-mapping of the methylation patterns for ARID5B
cg25953130 loci is also needed. Taken together with the existing
chromatin-capture sequencing and histone marks data, the
integration of our methylomic and transcriptomic data identiﬁes
the intronic region, where the ARID5B CpG (cg25953130)
resides, most likely being in the ARID5B enhancer. Our
mediation analysis further suggests that the ARID5B methylation
association with atherosclerosis is possibly via an epigenetically
controlled enhancer that supports promoter activation and
ARID5B transcription.
Importantly, our in vitro experiments support a novel func-
tional role of ARID5B in immune and metabolic homeostasis.
We found that ARID5B knockdown limited LPS-stimulated gene
expression increases in pro-inﬂammatory and interferon signal-
ing pathways50. The ARID5B-regulated genes are expected to
increase the activation state of atherosclerosis-relevant functions,
including leukocyte chemotaxis, migration, extravasation, and
phagocytosis, as well as lipid synthesis. We further demonstrated
ARID5B knockdown inhibited monocyte migration and phago-
cytosis when deregulated by persistent stress signals. Chronic
inﬂammation and its related functional changes in monocytes are
well-recognized mechanisms in atherosclerosis9, 10. The ARID5B-
dependent pro-inﬂammatory response was consistent with the
positive correlation between ARID5B expression and plasma IL-6
levels that we observed in MESA. We also conﬁrmed the role of
ARID5B in lipid metabolism that implicated previously29. Col-
lectively, our ﬁndings suggest that increased ARID5B expression
promotes atherosclerosis by dysregulating immunometabolism
towards a chronic inﬂammatory phenotype.
Given the role of ARID5B in chromatin state dynamics44, 48,
we speculate that ARID5B with its histone cofactor PHF2
demethylase are at a pivotal gene regulatory axis that epigeneti-
cally controls immune and metabolic homeostasis. Conceptually,
altering the ARID5B-regulated H3K9me2 repressor state known
to exist for proinﬂammatory gene silencing in monocytes51 may
convert poised enhancers and promoters to an active state52,
therefore directing expression of the gene pathways observed in
this population and the in vitro study. Searching for predicted
ARID5B binding site motifs (conserved in the human, mouse,
and rat sequence alignments), we identiﬁed potential ARID5B-
binding sites within 20 kb of 760 genes with decreased expression
following ARID5B knockdown, which include key genes for
proinﬂammation (e.g., TNF, IL-1α, and IFNB1). Chronic
inﬂammation perturbs immunometabolic homeostasis, con-
tributing to the development of many common diseases and to
the aging process. Further investigation of the role of the
ARID5B-PHF2 epigenetic axis in chronic inﬂammation is criti-
cally needed. Finally, our ﬁndings indicate that blood monocytes
obtained from large epidemiologic investigations of normal vs.
chronic inﬂammation states such as atherosclerosis can be
combined with human cell culture models to illuminate mole-
cular immunometabolic pathways and inform novel targets for
prevention and intervention of atherosclerosis.
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00517-4 ARTICLE
NATURE COMMUNICATIONS |8:  393 |DOI: 10.1038/s41467-017-00517-4 |www.nature.com/naturecommunications 9
Methods
Participants. The present analyses are primarily based on data collected at MESA
Exam 5 (April 2010–February 2012) with concurrent analyses of puriﬁed monocyte
samples of 1264 randomly selected MESA participants from four MESA sites (John
Hopkins University, Columbia University, University of Minnesota, and Wake
Forest University). The study protocol was approved by Institutional Review
Boards of the four institutions. All participants signed informed consent.
Measurement of atherosclerosis and prevalent CVD. All measurements in
humans were obtained at MESA Exam 5 unless otherwise speciﬁed. To obtain
carotid artery plaque scores, readers at the UW Atherosclerosis Imaging Research
Program Laboratory adjudicated carotid plaque presence or absence, deﬁned as a
focal abnormal wall thickness (carotid IMT> 1.5 mm) or a focal thickening of
> 50% of the surrounding IMT, as reported previously19, 53. The presence or
absence of plaque acoustic shadowing was recorded. A total plaque score (range
0–12) was calculated to describe carotid plaque burden. One point per plaque was
allocated for the near and far walls of each segment (common carotid artery, bulb,
and internal carotid artery) of each carotid artery that was interrogated. For carotid
plaque presence, intra-reader reproducibility was excellent (per reader κ= 0.82–1.0,
overall κ= 0.83, 95% CI 0.70–0.96), as was inter-reader reproducibility (κ= 0.89;
95% CI 0.72–1.00)54. The CT Reading Center for cardiac scans in the MESA is at
UCLA-Biomedical Research Institute. Coronary artery calcium (CAC) score was
determined using the Agatston method, which accounts for both lesion area and
calcium density using Hounsﬁeld brightness. The re-read agreement for the CAC
score (intraclass correlation coefﬁcient = 0.99) was excellent. Prevalent CVD was
deﬁned as a past history of myocardial infarction, angina (which included deﬁnite
angina and probable angina if coronary revascularization was performed at the
same time or afterwards), resuscitated cardiac arrest, or stroke.
Measurement of covariates. Weight was measured with a Detecto Platform
Balance Scale to the nearest 0.5 kg. Height was measured with a stadiometer
(Accu-Hite Measure Device with level bubble) to the nearest 0.1 cm. BMI was
deﬁned as weight in kilograms divided by square of height in meters. T2DM was
deﬁned as fasting glucose≥ 7.0 mmol l−1 (≥ 126 mg dl−1) or use of hypoglycemic
medication, and impaired fasting glucose was deﬁned as fasting glucose 5.6–6.9
mmol l−1 (100–125 mg dl−1). Plasma IL-6 was measured by ultra-sensitive ELISA
(Quantikine HS Human IL-6 Immunoassay; R&D Systems, Minneapolis, MN).
Plasma C-reactive protein (CRP) was measured using the BNII nephelometer
(High-Sensitivity CRP; Dade Behring Inc., Deerﬁeld, IL). Resting blood pressure
was measured three times in the seated position using a Dinamap model Pro 100
automated oscillometric sphygmomanometer (Critikon, Tampa, FL). The average
of the last two measurements was used in analysis. Hypertension was deﬁned as
systolic pressure ≥140 mmHg, diastolic pressure ≥90 mmHg, or current use of
anti-hypertensive medication. The single nucleotide polymorphisms (SNPs) data
were derived from MESA Affymetrix 6.0 array genotype data55.
Blood cell count and puriﬁcation of CD14+ and CD4+ cells. Samples for
complete blood count with differential analysis were obtained by venipuncture and
collected into tubes containing EDTA. Total circulating WBC count and cell
subtype counts were performed at local LabCorp. Blood was also collected in
sodium heparin-containing Vacutainer CPT cell separation tubes (Becton
Dickinson, Rutherford, NJ) to separate peripheral blood mononuclear cells from
other elements within two hours from blood draw. Subsequently, monocytes and
T cells were isolated with anti-CD14 and anti-CD4 monoclonal antibody-coated
magnetic beads, respectively, using an autoMACS automated magnetic separation
unit (Miltenyi Biotec, Bergisch Gladbach, Germany). Initially, ﬂow cytometry
analysis of 18 specimens was performed, including samples from all four MESA
ﬁeld centers, which were found to be consistently > 90% pure.
DNA/RNA extraction. DNA and RNA were isolated from samples simultaneously
using the AllPrep DNA/RNA Mini Kit (Qiagen, Inc., Hilden, Germany). DNA and
RNA quality control (QC) metrics included optical density measurements, using a
NanoDrop spectrophotometer and evaluation of the integrity of 18 and 28 s
ribosomal RNA using the Agilent 2100 Bioanalyzer with RNA 6000 Nano chips
(Agilent Technology, Inc., Santa Clara, CA) following manufacturer’s instructions.
RNA with RIN (RNA Integrity) scores> 9.0 was used for global expression
microarrays. The median of RIN for our 1264 samples was 9.9.
Global mRNA expression quantiﬁcation. The Illumina HumanHT-12 v4
Expression BeadChip and Illumina Bead Array Reader were used to perform the
genome-wide expression analysis, as previously described22. This data has been
deposited in the NCBI Gene Expression Omnibus and is accessible through GEO
Series accession number (GSE56047).
Epigenome-wide methylation quantiﬁcation. Illumina HumanMethylation450
BeadChips and HiScan reader were used to perform the epigenome-wide methy-
lation analysis, as previously described22. This methylation data has been deposited
in the NCBI Gene Expression Omnibus and is accessible through GEO Series
accession number (GSE56046).
QC and pre-processing of microarray data. Data pre-processing and QC
analyses were performed in R (http://www.r-project.org/) using Bioconductor
(http://www.bioconductor.org/) packages, as previously described22. For both
monocyte and T-cell assays, we included 2% blind duplicates. Correlations among
technical replicates exceeded 0.997. Multidimensional scaling plots showed the ﬁve
common control samples were highly clustered together and identiﬁed three outlier
samples, which were excluded subsequently.
The Illumina HumanHT-12 v4 Expression BeadChip included > 47,000 probes
for > 30,000 genes (with unique Entrez gene IDs). Statistical analyses excluded
probes with non-detectable expression in ≥ 90% of MESA samples (using a
detection p-value cutoff of 0.0001), probes overlapping repetitive elements or
regions, probes with low variance across the samples (< 10th percentile), or probes
targeting putative and/or not well-characterized genes, i.e., gene names starting
with KIAA, FLJ, HS, MGC, or LOC; 14,619 mRNA transcripts from 10,989 unique
genes were included in the analyses of the presented manuscript.
The Illumina HumanMethylation450 BeadChip included probes for 485 K CpG
sites. Exclusion criteria included probes with “detected” methylation levels in
< 90% of MESA samples using a detection p-value cutoff of 0.05 and 65 control
probes which assay highly polymorphic SNPs rather than DNA methylation56.
Methylation data for the total of 484,817 CpG sites were included in the analyses.
To estimate residual sample contamination, we generated separate enrichment
scores for neutrophils, B cells, T cells, and natural killer cells as described
previously22. We adjusted for residual sample contamination with non-monocyte
cell types in all the analyses. Although most of monocytes (80–90%) are expected to
be CD14+ CD16−23, we also adjusted for expression of the FCGR3a gene (CD16a).
RNA sequencing. A subset of 374 samples was randomly selected from the 1,264
MESA monocyte samples for RNA sequencing (see the Supplementary Methods
for details).
Bisulﬁte treatment of genomic DNA and pyrosequencing. A subset of 90
samples was selected from the 1264 MESA monocyte samples, based on carotid
plaque score extremes, matched for age, sex, and race (see the Supplementary
Methods for details).
Weighted gene co-expression network analyses. The WGCNA method was
used to construct network modules of highly correlated transcripts, using the
R package WGCNA31. A total of 1261 MESA samples were included in the
co-expression network analysis after removing 3 outlier samples based on
hierarchical clustering and 13,196 mRNA transcripts were included. First, we
constructed an unsigned weighted network based on the pairwise correlations
among all transcripts considered, using a soft thresholding power of 5, chosen to
produce approximately a scale-free topology. Then, using the topological overlap
measure to estimate the network interconnectedness, the transcripts were
hierarchically clustered. We used the default parameters of WGCNA, except for
changing the correlation type from Pearson to biweight midcorrelation (which is
more robust to outliers), the deepSplit setting from 2 to 3, the detectCutHeight
value from 0.995 to 0.999, the maximum block size from 5000 to 14,000
transcripts, and the minimum size for module detection from 20 to 10.
WGCNA produces a set of modules, each containing a unique set of mRNA
transcripts. The module eigengene was obtained to represent each module, which
corresponds to the ﬁrst eigenvector of the within-module expression correlation
matrix (or the ﬁrst right-singular vector of the standardized within-module
expression matrix).
Association analyses. The overall goal of the association analysis was to
characterize the associations of each measure of atherosclerosis (carotid plaque
and CAC) with each of genome-wide measures of mRNA expression and DNA
methylation. Analyses were performed using the linear model (lm) function of the
Stats package and the stepAIC function of the MASS package in R. Reported
correlations (r) represent the partial Pearson product-moment correlation
coefﬁcient. We ﬁt separate linear regression models for each measure of athero-
sclerosis, with (1) genome-wide (log2 transformed) mRNA expression proﬁles,
(2) network module eigengenes from WGCNA, and (3) genome-wide DNA
methylation proﬁles (M-values). The M-value is well suited for high-level analyses
and can be transformed into the β-value, an estimate of the percent methylation of
an individual CpG site that ranges from 0 to 1 (M is logit(β-value)). The p-values
were adjusted for multiple testing using the q-value FDR method27 and
Benjamini–Hochberg FDR57 when applicable. All analyses accounted for effects of
residual cell contamination and covariates including age, gender, ethnicity, and
study site. The full model also adjusted for traditional CVD risk factors (cigarette
smoking, BMI, HDL-C and LDL-C levels, hypertension, and diabetes mellitus) and
statin use.
Mediation analysis. To investigate the genomic features as a potential molecular
link between CVD risk factors and extent of atherosclerosis, we performed
mediation analyses under an assumed causal model in which a CVD risk factor
leads to a change in the genomic feature, which at least partially mediates the
effects of the CVD risk factor on atherosclerotic burden. The mediation analyses
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accounted for the biological and technical covariates and were performed by robust
SEM as implemented in the R package lavaan43. SEM analysis in general, and as
implemented in lavaan, is based on maximum likelihood and the normal dis-
tribution, but provides several approaches to effectively deal with non-normal data.
A ﬁrst approach consists of computing robust SE by sandwich-type covariance
matrices and scaled test statistics, in particular the Satorra–Bentler statistic whose
amount of rescaling reﬂects the degree of kurtosis, whereas the second approach
uses speciﬁc bootstrapping methods to obtain both SE and test statistics43. The
results we report are based on bootstrapping which we found to be somewhat more
conservative than the use of robust SE and the Satorra–Bentler statistic.
In vivo functional annotation analysis. CpGs with methylation signiﬁcantly
associated with carotid plaque scores or CAC were investigated for association with
cis-gene expression by performing a look-up in the results from our previous
analysis22 of the same samples. Brieﬂy, to identify DNA methylation associated
with gene expression in cis, we ﬁt separate linear regression models with the
M-value for each CpG site (adjusted for methylation chip and position effects) as a
predictor of transcript expression for any autosomal gene within 1Mb of the CpG
in question. Covariates were age, sex, and race/ethnicity, and study site.
mRNA expression and DNA methylation of the most signiﬁcantly associated
mRNA and CpGs associated with carotid plaques scores and CAC were also
investigated for association with nearby genetic variants. We arbitrarily chose to
investigate a large window (± 1Mb) surrounding the mRNA/CpG to avoid missing
any potential effects. Covariates were age, sex, and race/ethnicity, and study site.
We ﬁt separate linear regression models with SNPs located within 1Mb as a
predictor of the mRNA expression (log2 transformed) or the methylation
(M-value) in the MESA samples from Caucasian participants, including SNPs with
a minor allele frequency > 0.05 in the MESA Caucasian population. P-values were
adjusted for multiple testing using the q-value FDR method27.
In silico functional annotation analysis. For the differentially expressed
co-expression modules, Ingenuity Pathway Analysis (IPA, QIAGEN, Redwood
City, www.qiagen.com/ingenuity) was used to examine the enrichment of canonical
pathways and biofunctions. In silico functional prediction of chromatin states in
monocytes was performed using ChromHMM35 to predict segmentation among
six states, based on histone modiﬁcations in monocyte samples from the
BLUEPRINTproject36, 37 (H3K27ac, H3K4me1, and H3K4me3) and ENCODE38
(H3K36me3). Other functional information utilized includes DNase hypersensitive
hotspot data in a monocyte sample (C001UY46) from the BLUEPRINT project36,
37, and transcription factor binding sites detected in any cell type from ENCODE38.
Data were accessed from the UCSC Genome Browser58 and the Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/).
Hi-C data in a B-cell line (GM12878)39–42, including the contact matrix heatmap
and virtual 4C results, were adapted from the YUE lab Hi-C Interactions and Virtual
4 C website (http://www.3dgenome.org, manuscript submitted for publication).
Functional evaluation of ARID5B using in vitro models. To examine the func-
tional role of ARID5B, we used small interfering RNA (siRNA)-mediated ARID5B
knockdown in LPS-stimulated human THP1-monocytes. Using the protocols as
described above, we performed transcriptomic proﬁling using the Illumina
HumanHT-12 v4 Expression BeadChip and measured ARID5B mRNA expression
by quantitative PCR.
Human monocytic THP-1 cell line was purchased from the American Tissue
Culture Collection. Cells were maintained in complete RPMI 1640 medium
(Invitrogen) supplemented with 100 units per ml of penicillin, 100 μg ml−1 of
streptomycin, 2 mM L-glutamine, and 10% fetal bovine serum (FBS, HyClone,
Logan, UT) in a humidiﬁed incubator with 5% CO2 at 37 °C.
Two target-speciﬁc siRNAs for ARID5B exon 8&9 (Life Technologies, siRNA
ID: s38579, designated as siARID5B 1 in Supplementary Fig. 4A) and for exon 6
(siRNA ID: s38580, designated as siARID5B 2 in Supplementary Fig. 4A) were used
initially to compare for the knockdown efﬁciency. Then, the siARID5B 1 (s38579)
was chosen for the remaining in vitro experiments. SiRNA transfection was
performed using THP1 monocytes that were split 24 h before transfection. 10 nM
of siARID5B were electronically transfected into THP-1 cells for 24 and 48 h using
Amaxa Human Monocyte Nucleofector Kit and an Amaxa nucleofector II device
(Lonza, Inc.). Scrambled siRNAs were transfected as negative controls. Samples
were incubated for 24 h, followed by 3 h of LPS (LPS: 100 ng ml−1) stimulation.
Levels of human ARID5B and cytokines presented in Supplementary Fig. 5 were
measured by quantitative real-time reverse transcriptase-PCR (RT-PCR) using
gene-speciﬁc TaqMan probe sets in an ABI prism 7000 sequence detection system
(Life Technologies). Glyceraldehyde 3-phosphate dehydrogense mRNA was the
internal loading control.
To reduce false-positive rates, two independent experiments (four siARID5B vs.
four scrambled siRNA samples per experiment) were performed. To detect
differential expression between two groups with small sample sizes, the regularized
t-test implemented in the limma R package was used59. For the differentially
expressed genes, IPA (QIAGEN, Redwood City, www.qiagen.com/ingenuity) was
used to examine the enrichment of canonical pathways and biofunctions.
To further interrogate the potential pro-inﬂammatory effect that ARID5B may
have, we repeated the third siARID5B knockdown experiment as described above
and performed ELISA assays of culture media for IL-1a, the pro-inﬂammatory
cytokine that was most signiﬁcantly reduced by ARID5B mRNA Knockdown.
Supernatants collected from LPS stimulated THP1 cells were analyzed for human
IL-1a production using commercial sandwich ELISA kit (R&D Systems) according
to the manufacturer’s instructions. The results are representative of three or more
experiments performed in triplicated as means + SEM. Levels of IL-1a mRNA
expression presented in Fig. 5b were measured by RT-PCR as described previously.
To further examine the effects of ARID5B knockdown on cellular functions
suggested by the transcriptomic proﬁle changes, we repeated the siARID5B
knockdown experiment as described above and performed THP1-monoctye
migration and phagocytosis assays. Cell migration was evaluated using Transwell
inserts (6.5 mm diameter) with polycarbonate ﬁlters (5-μm pore size, Corning
Costar) in 24-well plates. THP1 cells (30,000 cells per well) were added to the upper
chamber of the insert. The lower chamber contained 600 μl of RPMI 1640 medium/
1% FBS with chemokine, MCP-1 (40 ng ml−1). The plates were incubated at 37 °C
in 5% CO2 for 24 h and cells that had migrated into the lower chamber were
counted using cell countess. Cell phagocytosis was evaluated using yellow–green
carboxylate-modiﬁed microspheres (Thermo Fisher Scientiﬁc) in 24-well plates.
Cells (500,000 cells per well) were incubated with 2 μl of beads (beads:cells = 5:1)
for 60 min. After thoroughly washing 10 times with cold PBS, % engulfed beads in
cells were calculated using ﬂuorescence-activated cell sorting.
Data availability. Genome-wide gene expression and DNA methylation data have
been deposited in the NCBI Gene Expression Omnibus (GEO) and is accessible
through GEO Series accession number GSE56047 and GSE56046, respectively.
Received: 15 March 2016 Accepted: 5 July 2017
References
1. Lewis, J. & Bird, A. DNA methylation and chromatin structure. FEBS Lett. 285,
155–159 (1991).
2. Bird, A. P. & Wolffe, A. P. Methylation-induced repression--belts, braces, and
chromatin. Cell 99, 451–454 (1999).
3. Jones, P. A. & Takai, D. The role of DNA methylation in mammalian
epigenetics. Science 293, 1068–1070 (2001).
4. Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease
and prospects for epigenetic therapy. Nature 429, 457–463 (2004).
5. Petronis, A. Epigenetics as a unifying principle in the aetiology of complex traits
and diseases. Nature 465, 721–727 (2010).
6. Reinius, L. E. et al. Differential DNA methylation in puriﬁed human blood cells:
implications for cell lineage and studies on disease susceptibility. PLoS ONE. 7,
e41361 (2012).
7. Lessner, S. M., Prado, H. L., Waller, E. K. & Galis, Z. S. Atherosclerotic lesions
grow through recruitment and proliferation of circulating monocytes in a
murine model. Am. J. Pathol. 160, 2145–2155 (2002).
8. Osterud, B. & Bjorklid, E. Role of monocytes in atherogenesis. Physiol. Rev. 83,
1069–1112 (2003).
9. Hansson, G. K. Inﬂammation, atherosclerosis, and coronary artery disease.
N. Engl. J. Med. 352, 1685–1695 (2005).
10. Ley, K., Miller, Y. I. & Hedrick, C. C. Monocyte and macrophage dynamics
during atherogenesis. Arterioscler. Thromb. Vasc. Biol. 31, 1506–1516 (2011).
11. Reynolds, L. M. et al. Age-related variations in the methylome associated with
gene expression in human monocytes and T cells. Nat. Commun. 5, 5366 (2014).
12. Reynolds, L. M. et al. Transcriptomic proﬁles of aging in puriﬁed human
immune cells. BMC Genomics 16, 333 (2015).
13. Ding, J. et al. Alterations of a cellular cholesterol metabolism network are a
molecular feature of obesity-related type 2 diabetes and cardiovascular disease.
Diabetes 64, 3464–3474 (2015).
14. Reynolds, L. M. et al. DNA methylation of the aryl hydrocarbon receptor
repressor associations with cigarette smoking and subclinical atherosclerosis.
Circ Cardiovasc. Genet 8, 707–716 (2015).
15. Bild, D. E. et al. Multi-ethnic study of atherosclerosis: objectives and design.
Am. J. Epidemiol. 156, 871–881 (2002).
16. Tattersall, M. C. et al. Predictors of carotid thickness and plaque progression
during a decade: the Multi-Ethnic Study of Atherosclerosis. Stroke 45,
3257–3262 (2014).
17. Gepner, A. D. et al. Comparison of coronary artery calcium presence, carotid
plaque presence, and carotid intima-media thickness for cardiovascular disease
prediction in the multi-ethnic study of atherosclerosis. Circ. Cardiovasc.
Imaging 8, e002262 (2015).
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00517-4 ARTICLE
NATURE COMMUNICATIONS |8:  393 |DOI: 10.1038/s41467-017-00517-4 |www.nature.com/naturecommunications 11
18. Plichart, M. et al. Carotid intima-media thickness in plaque-free site,
carotid plaques and coronary heart disease risk prediction in older adults. The
Three-City Study. Atherosclerosis. 219, 917–924 (2011).
19. Stein, J. H. et al. Use of carotid ultrasound to identify subclinical vascular
disease and evaluate cardiovascular disease risk: a consensus statement from the
American Society of Echocardiography Carotid Intima-Media Thickness Task
Force. Endorsed by the Society for Vascular Medicine. J. Am. Soc. Echocardiogr.
21, 93–111 (2008).
20. Madjid, M., Awan, I., Willerson, J. T. & Casscells, S. W. Leukocyte count and
coronary heart disease: implications for risk assessment. J. Am. Coll. Cardiol.
44, 1945–1956 (2004).
21. Lyons, P. A. et al. Microarray analysis of human leucocyte subsets: the advantages
of positive selection and rapid puriﬁcation. BMC Genomics 8, 64 (2007).
22. Liu, Y. et al. Methylomics of gene expression in human monocytes. Hum. Mol.
Genet. 22, 5065–5074 (2013).
23. Wong, K. L. et al. Gene expression proﬁling reveals the deﬁning features of the
classical, intermediate, and nonclassical human monocyte subsets. Blood 118,
e16–e31 (2011).
24. Berisha, S. Z., Hsu, J., Robinet, P. & Smith, J. D. Transcriptome analysis of
genes regulated by cholesterol loading in two strains of mouse macrophages
associates lysosome pathway and ER stress response with atherosclerosis
susceptibility. PLoS ONE 8, e65003 (2013).
25. Maiwald, S., Zwetsloot, P. P., Sivapalaratnam, S. & Dallinga-Thie, G. M.
Monocyte gene expression and coronary artery disease. Curr. Opin. Clin. Nutr.
Metab. Care 16, 411–417 (2013).
26. Sivapalaratnam, S. et al. Monocyte gene expression signature of patients with
early onset coronary artery disease. PLoS ONE 7, e32166 (2012).
27. Storey, J. D. & Tibshirani, R. Statistical signiﬁcance for genomewide studies.
Proc. Natl. Acad. Sci. USA 100, 9440–9445 (2003).
28. Whitson, R. H., Tsark, W., Huang, T. H. & Itakura, K. Neonatal mortality and
leanness in mice lacking the ARID transcription factor Mrf-2. Biochem.
Biophys. Res. Commun. 312, 997–1004 (2003).
29. Yamakawa, T., Whitson, R. H., Li, S. L. & Itakura, K. Modulator recognition
factor-2 is required for adipogenesis in mouse embryo ﬁbroblasts and 3T3-L1
cells. Mol. Endocrinol. 22, 441–453 (2008).
30. Wong, A. M. et al. Characterization of CACNA2D3 as a putative tumor
suppressor gene in the development and progression of nasopharyngeal
carcinoma. Int. J. Cancer 133, 2284–2295 (2013).
31. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation
network analysis. BMC Bioinformatics 9, 559 (2008).
32. Shenker, N. S. et al. Epigenome-wide association study in the European
Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identiﬁes
novel genetic loci associated with smoking. Hum. Mol. Genet. 22, 843–851
(2013).
33. Du, P. et al. Comparison of Beta-value and M-value methods for quantifying
methylation levels by microarray analysis. BMC Bioinformatics 11, 587 (2010).
34. Jones, P. A. Functions of DNA methylation: islands, start sites, gene bodies and
beyond. Nat. Rev. Genet. 13, 484–492 (2012).
35. Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and
characterization. Nat. Methods 9, 215–216 (2012).
36. Adams, D. et al. BLUEPRINT to decode the epigenetic signature written in
blood. Nat. Biotechnol. 30, 224–226 (2012).
37. Saeed, S. et al. Epigenetic programming of monocyte-to-macrophage
differentiation and trained innate immunity. Science 345, 1251086 (2014).
38. Rosenbloom, K. R. et al. ENCODE data in the UCSC Genome Browser: year 5
update. Nucleic Acids Res. 41, D56–D63 (2013).
39. Rao, S. S. et al. A 3D map of the human genome at kilobase resolution reveals
principles of chromatin looping. Cell 159, 1665–1680 (2014).
40. Dixon, J. R. et al. Topological domains in mammalian genomes identiﬁed by
analysis of chromatin interactions. Nature 485, 376–380 (2012).
41. Heidari, N. et al. Genome-wide map of regulatory interactions in the human
genome. Genome Res. 24, 1905–1917 (2014).
42. Dixon, J. R. et al. Chromatin architecture reorganization during stem cell
differentiation. Nature 518, 331–336 (2015).
43. Rosseel, Y. lavaan: an R package for structural equation modeling. J. Stat. Softw.
48, 1–36 (2012).
44. Hata, K. et al. Arid5b facilitates chondrogenesis by recruiting the histone
demethylase Phf2 to Sox9-regulated genes. Nat Commun. 4, 2850 (2013).
45. Yang, W. et al. Meta-analysis followed by replication identiﬁes loci in or near
CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic
lupus erythematosus in Asians. Am. J. Hum. Genet. 92, 41–51 (2013).
46. Okada, Y. et al. Meta-analysis identiﬁes nine new loci associated with
rheumatoid arthritis in the Japanese population. Nat. Genet. 44, 511–516 (2012).
47. Watanabe, M. et al. Regulation of smooth muscle cell differentiation by AT-rich
interaction domain transcription factors Mrf2alpha and Mrf2beta. Circ. Res. 91,
382–389 (2002).
48. Baba, A. et al. PKA-dependent regulation of the histone lysine demethylase
complex PHF2-ARID5B. Nat. Cell. Biol. 13, 668–675 (2011).
49. Gerstein, M. B. et al. Architecture of the human regulatory network derived
from ENCODE data. Nature 489, 91–100 (2012).
50. Lu, Y. C., Yeh, W. C. & Ohashi, P. S. LPS/TLR4 signal transduction pathway.
Cytokine. 42, 145–151 (2008).
51. El, G. M. et al. G9a and HP1 couple histone and DNA methylation to
TNFalpha transcription silencing during endotoxin tolerance. J. Biol. Chem.
283, 32198–32208 (2008).
52. Romanoski, C. E., Glass, C. K., Stunnenberg, H. G., Wilson, L. & Almouzni, G.
Epigenomics: roadmap for regulation. Nature 518, 314–316 (2015).
53. Touboul, P. J. et al. Mannheim carotid intima-media thickness consensus
(2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th
Watching the Risk Symposium, 13th and 15th European Stroke Conferences,
Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc. Dis. 23,
75–80 (2007).
54. Tattersall, M. C. et al. Predictors of carotid thickness and plaque progression
during a decade: the multi-ethnic study of atherosclerosis. Stroke 45, 3257–3262
(2014).
55. Fox, C. S. et al. Genome-wide association of pericardial fat identiﬁes a unique
locus for ectopic fat. PLoS Genet. 8, e1002705 (2012).
56. Pidsley, R. et al. A data-driven approach to preprocessing Illumina 450K
methylation array data. BMC Genomics 14, 293 (2013).
57. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (2006).
58. Karolchik, D. et al. The UCSC Genome Browser database: 2014 update. Nucleic
Acids Res. 42(D1), D764–D770 (2014).
59. Smyth, G. K. Linear models and empirical bayes methods for assessing differential
expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
Acknowledgements
This research was supported by contracts N01-HC-95159, N01-HC-95160,
N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165,
N01-HC-95166, N01-HC-95167, N01-HC-95168, and N01-HC-95169, and R01 HL
119962 from the National Heart, Lung, and Blood Institute. The MESA Epigenomics and
Transcriptomics Studies were funded by R01HL101250, R01 DK103531-01, R01
DK103531, R01 AG054474, and R01 HL135009-01 to Wake Forest University Health
Sciences. The research described in this publication was funded in part by the U.S.
Environmental Protection Agency through RD831697 to the University of Washington
(MESA Air); it has not been subjected to the Agency’s required peer and policy review
and therefore does not necessarily reﬂect the views of the Agency and no ofﬁcial
endorsement should be inferred.
Author contributions
Conceptualization: Y.L., J.D., D.H., R.P.T., C.M., J.H.S. Methodology: Y.L., I.H., J.D.,
R.P.T., C.E.M., J.H.S., L.M.R. Investigation: Y.L., L.M.R., J.D., L.H., K.L., T.Y., W.C., M.
W., H.G.S., J.P., D.S., L.H., B.M.P., S.S.R, J.I.R., J.D.K., G.L.B., D.R.J., W.P., I.H., D.A.B.,
R.P.T., D.H., C.E.M., J.H.S. Writing, original draft: Y.L., L.M.R., J.D., R.P.T., C.M., J.H.S.
Writing, review and editing: Y.L., L.M.R., J.D., M.W., H.G.S., J.P., D.S., L.H., B.M.P.,
S.S.R, J.I.R., J.D.K., G.L.B., D.R.J., W.P., I.H., D.A.B., D.H., R.P.T., C.E.M., J.H.S.
Visualization: Y.L., L.M.R., K.L. Funding acquisition, Y.L., I.H., J.D., D.H., R.P.T., C.E.M.,
J.H.S. Supervision, Y.L.
Additional information
Supplementary Information accompanies this paper at doi:10.1038/s41467-017-00517-4.
Competing interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2017
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00517-4
12 NATURE COMMUNICATIONS |8:  393 |DOI: 10.1038/s41467-017-00517-4 |www.nature.com/naturecommunications
